Clinical Trials Logo

Anti-MAG Neuropathy clinical trials

View clinical trials related to Anti-MAG Neuropathy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05136976 Recruiting - Anti-MAG Neuropathy Clinical Trials

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders

THERAMAG
Start date: June 29, 2023
Phase: Phase 3
Study type: Interventional

Anti-MAG neuropathy is a progressively disabling orphan rare disorder due to a monoclonal immunoglobulin M(IgM) gammopathy displaying reactivity toward MAG, a glycoprotein of the peripheral nervous system. Its prevalence is around 1/100000 and to date, no treatment has proven efficacy in this disease, including rituximab in 2 Randomized Controlled Trails(RCTs).